Company intelligence / Profile preview

Intra-ImmuSG

Ownership: Private
Development stage: Phase 2

Overview

PRL3-zumab has completed a successful Phase II clinical trial with excellent drug safety profile and positive efficacy signals. It has shown potential for treating patients who are no longer suitable for immunotherapy or chemotherapy, with longer Progress Free Survival than prior treatments without drug-related toxicity[3].

Therapeutic areas: Oncology
Modalities: Humanized antibody drugsMonoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

PRL3-zumab

Beyond the preview

Go deeper on Intra-ImmuSG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intra-ImmuSG.

Explore the full profile